The Australian reports the successful conclusion of Racura’s lead drug AML study

The Australian reports the conclusion of Racura’s Phase 1b/2 investigator-sponsored trial of RC110 bisantrene in relapsed or refractory acute myeloid leukaemia patients, conducted at the Chaim Sheba Medical Centre in Israel and led by Professor Arnon Nagler.

The results show that 40% of patients with highly advanced disease showing a response to bisantrene.

Read the full article here.